Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is Pterygoid hamulus fracture a pre requisite for cleft palate surgery? - A Systematic review of surgical, otologic, and speech outcomes.

International journal of pediatric otorhinolaryngology·2026

Same author

Clinical Implications of Early vs Late Development of Donor-Specific Antibodies Among Lung Transplant Recipients: A Single-Center Experience.

Clinical transplantation·2026

Same author

Development of whole virion inactivated Kyasanur Forest Disease vaccine candidate and its preclinical safety and efficacy evaluation.

Frontiers in immunology·2026

Same author

Effect of interrupted agitation on quality of random donor platelets: A pilot study.

Medical journal, Armed Forces India·2026

Same author

Clinical-Radiological Outcomes of Early Versus Delayed Weight-Bearing Following Proximal Femoral Nail Antirotation 2 Fixation for Intertrochanteric Fractures: A Prospective Randomized Comparative Study.

Cureus·2026

Same author

Impact of Preoperative Statin Augmentation on Myocardial Injury Assessed by Biomarkers and Strain Parameters in Off-Pump Coronary Artery Bypass Grafting.

Cureus·2026

Same journal

The utility of human challenge studies in vaccine development: lessons learned from cholera.

Vaccine (Auckland, N.Z.)·2014

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 20, 2026

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Published on: September 30, 2017

Tularemia vaccine development: paralysis or progress?

Raju Sunagar¹, Sudeep Kumar¹, Brian J Franz¹

¹Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY, USA.

Vaccine (Auckland, N.Z.)

|May 21, 2016

Summary

This summary is machine-generated.

Developing a US Food and Drug Administration-approved vaccine for Francisella tularensis (Ft), a dangerous biothreat agent, remains challenging. This review examines research progress and factors affecting vaccine efficacy, assessing future prospects.

Keywords:

Sex bias cellular immunity differential protection humoral immunity media impact

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Mar 20, 2026

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Published on: September 30, 2017

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Microbiology
Vaccinology
Biodefense

Background:

Francisella tularensis (Ft) is a Gram-negative bacterium classified as a Category A biothreat agent.
Despite significant investment and research over 15 years, a US Food and Drug Administration (FDA)-approved vaccine against Ft is still unavailable.

Purpose of the Study:

To review the research efforts dedicated to developing an Ft vaccine.
To identify key factors influencing the development and evaluation of Ft vaccine efficacy.
To assess the likelihood of an FDA-approved Ft vaccine and potential pathways to achieve it.

Main Methods:

Literature review of Ft vaccine research.
Analysis of factors impacting vaccine efficacy.
Assessment of current vaccine development landscape and future strategies.

Main Results:

The development of an effective Ft vaccine faces significant hurdles.
Several factors, some recently identified, critically influence vaccine efficacy and evaluation.
The path to an FDA-approved Ft vaccine is complex and requires addressing these multifaceted challenges.

Conclusions:

Achieving an FDA-approved Francisella tularensis vaccine remains a critical unmet need in biodefense.
Further research and strategic approaches are necessary to overcome existing challenges in Ft vaccine development.
Understanding and addressing the identified factors is crucial for the successful development of a protective Ft vaccine.